Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2016. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) under the GlaxoSmithKline Performance Share Plan (PSP). The transactions were executed on February 12, 2016, to meet tax liabilities following the vesting of awards granted in 2012.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific share transaction prices:
- Ordinary Share Price: £14.06 per share (used for sales to meet tax liabilities).
- American Depositary Share (ADS) Price: $39.15 per ADS (used for withholding to meet tax liabilities).
Material Changes
The filing details changes in shareholdings for specific executives and directors due to tax withholding events. There are no reported material changes to the company's business operations, financial position, or strategic direction in this document.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, outlook, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of insider trading activity related to compensation vesting.
Important Facts for Investors
- Transaction Type: Sales and withholdings of shares were conducted solely to satisfy tax obligations arising from the vesting of 2012 Performance Share Plan awards.
- Executive Activity: Executive Directors Sir Andrew Witty and Dr. M. Slaoui were among those with significant share reductions (68,158 Ordinary Shares and 26,557 ADSs, respectively).
- Timing: Transactions occurred on February 12, 2016, and were notified to the company on February 16, 2016.
- Scope: The filing does not contain financial performance data for the company.